

**AMENDMENTS TO THE SPECIFICATION**

Please delete the Sequence Listing in electronic form previously submitted and replace with the Sequence Listing submitted herewith in text file *via* EFS-Web.

In the specification at page 1, please replace the paragraph entitled “INCORPORATION OF SEQUENCE LISTING” inserted in the Preliminary Amendment dated March 3, 2006 with the following new paragraph:

**SEQUENCE LISTING SUBMISSION**

The Sequence Listing associated with this application is filed in electronic format *via* EFS-Web and hereby incorporated by reference into the specification in its entirety. The name of the text file containing the Sequence Listing is Sequence\_Listing\_14129\_00001. The size of the text file is 741 KB, and the text file was created on July 11, 2008.

In the specification at page 18, line 24, please replace the paragraph which starts with “In a preferred embodiment” with the following amended paragraph:

In a preferred embodiment, the FADS2 inhibitor is either a siRNA with the sequences: GCUGAAAUACCUGCCCUAC (SEQ ID NO: 126) or GCAUGGCAUUGAAUACCAG (SEQ ID NO: 127) or the compound SC-26196 (see Obukowicz, *supra*).

In the specification at page 377, line 7, please replace the paragraph which starts with “The sequences used” with the following amended paragraph:

The sequences used for FADS2 are: GCUGAAAUACCUGCCCUAC (SEQ ID NO: 126) and GCAUGGCAUUGAAUACCAG (SEQ ID NO: 127)